ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD)

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

ANANDA Scientific Inc ., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDAs proprietary Liquid Structure delivery technology as a potential treatment for Social Anxiety Disorder.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, November 30, 2022
Information
Tags: 
Research, FDA, Cannabis, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Natural Resources, Trier social stress test, Cannabidiol, US Food Sovereignty Alliance, Principal investigator, Doctor of Philosophy, Alternative medicine, Food, Multimedia, IND, New York University Grossman School of Medicine, Master of Science, National Center for Health Research, Prolonged exposure therapy, Cannabinoid, NYU, Neuroimaging, TSST, UCLA, Psychiatry, Assistant, NIH, Social anxiety disorder, Research, PTSD, LDS, Clinical trial, FDA, Pharmaceutical industry, Medical device, Anxiety, MD, CBD
Geotags: 
NEW YORK, COLORADO, UNITED STATES, NORTH AMERICA, ISRAEL
⚠ partially generated by AI ↴
Organisation: 
ANANDA SCIENTIFIC, ANANDA SCIENTIFIC INC.
Summary
Key Points: 
  • ANANDA Scientific Inc ., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDAs proprietary Liquid Structure delivery technology as a potential treatment for Social Anxiety Disorder.
  • ( Clinical Trials.gov Identifier: NCT05571592 )
    This press release features multimedia.
  • We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition, said Dr Simon.
  • ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD , Radiculopathic Pain , Anxiety and Opioid Use Disorder ( Mt.


ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005218/en/

(Photo: Business Wire)

(Photo: Business Wire)

The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.

“We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition,” said Dr Simon.

Dr. Blessing noted, “It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders.”

“We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people,” said Sohail R. Zaidi, ANANDA’s CEO. “We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need.”

ABOUT ANANDA SCIENTIFIC

ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder (Mt. Sinai and UCLA). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd, in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.

Copyright: 
Copyright Business Wire 2022